Docterz Raises Rs 5 Cr, With Doctors Using The Platform Putting In Nearly 60%

Docterz, a healthcare technology company founded by practising paediatrician Dr Atish Laddad, has raised Rs 5 crore from about 35 investors. Nearly 60% of the money, close to Rs 3 crore, came from roughly 20 doctors who use the platform.

The investor group also includes Vineeta Singh, co-founder and chief executive of SUGAR Cosmetics, and Avnish Anand, co-founder and former chief executive of CaratLane.

The Unusual Part of This Round

Indian healthtech has spent a decade building products for patients and hospitals. Software built for the individual doctor’s own practice is a smaller, less glamorous market, and it is the one where doctors actually pay.

Read More: Simplismart Raises $14 Mn Series B Led By Dallas Venture Capital, NVIDIA Joins

FundingClinics On Cloud Raises Rs 120 Cr At Rs 600 Cr Valuation After 8 Bootstrapped YearsFundingPracto Co-Founder Shashank ND’s Cent Raises $15 Mn, Acquires Medsee

Most healthtech rounds are led by funds. This one was led by customers, which is a different kind of validation.

Read More: Ex-Slice Executive’s QwikBuild Raises $2.3 Mn, Plans Japan Joint Venture With Globalway

A doctor who has run his clinic on a software product for years knows exactly where it breaks. When 20 of them put money in, the signal is not enthusiasm. It is usage.

Dr Dhananjay Sangle, a paediatrician and Docterz user-investor, said he has used the platform across his clinic’s paediatric and OB-GYN practices for several years and found it smooth and fast. That is the kind of sentence a pitch deck cannot manufacture.

What Docterz Actually Does

Docterz builds software for running a clinic, sold directly to doctors rather than to hospitals. That means appointments, documentation, staff management and follow-ups. It also covers the daily administrative load that sits between a doctor and a patient.

The product positions itself around three things that matter to Indian doctors. They are patient data security, clinical independence, and protecting the doctor-patient relationship from a marketplace.

That last point is a deliberate contrast with consumer health platforms. Docterz is not trying to own the patient; it is trying to own the doctor’s workflow, which is a quieter and stickier position.

Why Doctors Buy Software and Rarely Switch

For Docterz, clinic software is a switching-cost business. Once patient records, appointment histories and billing sit inside a system, moving means disruption, retraining and risk.

That is why the doctor-investor round matters commercially as much as financially. A user who owns equity becomes a reference customer. In a market sold doctor to doctor, references are the entire go-to-market.

What the Money Is For

Dr Laddad said the funding will go towards organic growth, exploring inorganic opportunities and building practical AI tools for doctors.

The phrase that matters is practical AI. Most clinical AI products in India fail because they add work rather than remove it. Tools that draft notes, summarise a visit or handle follow-ups save a doctor time. Tools that need new data entry do not.

Inorganic growth is the second signal. Rs 5 crore is small for acquisitions, but it is enough to buy a small competitor’s customer base, which is a faster route to scale than selling one clinic at a time.

What to Watch

Three things will show whether this is a durable business. The first is retention measured in years, not months, and the number of clinics running the full product rather than a single module.

The second is whether the AI features actually reduce a doctor’s working hours. If they do, pricing power follows. If they do not, they become free features that cost money to run.

The third is the cap table behind Docterz itself. A round funded mostly by customers is a strong vote of confidence and a weak source of follow-on capital. The next cheque will have to come from a fund, and that fund will ask for the metrics this round did not need.